Gennova gets DCGI nod to conduct Phase 2,3 trials of its mRNA COVID-19 vaccine


Gennova gets DCGI nod to conduct Phase 2,3 trials of its mRNA COVID-19 vaccine The study will be conducted in India at 10-15 sites in Phase II and 22-27 sites in Phase III. Gennova plans to use the DBT-ICMR clinical trial network sites for the study.